Freeline Therapeutics Holdings plc
NASDAQ:FRLN
6.49 (USD) • At close February 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.74 | 2.39 | 1.928 | 1.546 | 0 |
| Gross Profit
| -1.74 | -2.39 | -1.928 | -1.546 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 66.203 | 95.431 | 76.149 | 47.043 | 34.191 |
| General & Administrative Expenses
| 30.655 | 44.568 | 26.3 | 16.601 | 6.79 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 30.655 | 44.568 | 26.3 | 16.601 | 6.79 |
| Other Expenses
| -1.571 | -2.091 | -15.269 | -10.595 | -0.39 |
| Operating Expenses
| 95.287 | 137.908 | 87.18 | 53.049 | 32.715 |
| Operating Income
| -98.447 | -142.379 | -102.449 | -63.644 | -40.981 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 9.843 | 2.33 | 6.256 | 9.876 | -0.471 |
| Income Before Tax
| -88.604 | -140.049 | -96.193 | -53.768 | -33.256 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.368 | 0.342 | 0.129 | 0.141 | 0.027 |
| Net Income
| -88.972 | -140.391 | -96.322 | -53.909 | -33.283 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| EPS Diluted
| -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| EBITDA
| -97.174 | -133.137 | -85.267 | -51.509 | -32.135 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |